SEARCH

SEARCH BY CITATION

References

  • 1
    Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 338S400S.
  • 2
    Attia J, Ray JG, Cook DJ, Douketis J, Ginsberg JS, Geerts WH. Deep vein thrombosis and its prevention in critically ill adults. Arch Intern Med 2001; 161: 126879.
  • 3
    Dentali F, Douketis JD, Gianni M, Lim W, Crowther MA. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Intern Med 2007; 146: 27888.
  • 4
    Mismetti P, Laporte-Simitsidis S, Tardy B, Cucherat M, Buchmuller A, Juillard-Delsart D, Decousus H. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomized clinical trials. Thromb Haemost 2000; 83: 149.
  • 5
    Lowe GD, Sandercock PA, Rosendaal FR. Prevention of venous thromboembolism after major orthopaedic surgery: is fondaparinux an advance? Lancet 2003; 362: 5045.
  • 6
    Lederle FA. Heparin prophylaxis for medical patients? Ann Intern Med 1998; 128: 76870.
  • 7
    Crowther MA, Cook DJ, Meade MO, Griffith LE, Guyatt GH, Arnold DM, Rabbat CG, Geerts WH, Warkentin TE. Thrombocytopenia in medical-surgical critically ill patients: prevalence, incidence, and risk factors. J Crit Care 2005; 20: 34853.
  • 8
    Crowther MA, Cook DJ, Griffith LE, Devereaux PJ, Rabbat CC, Clarke FJ, Hoad N, McDonald E, Meade MO, Guyatt GH, Geerts WH, Wells PS. Deep venous thrombosis: clinically silent in the intensive care unit. J Crit Care 2005; 20: 33440.
  • 9
    Wells PS, Anderson DR, Bormanis J, Guy F, Mitchell M, Gray L, Clement C, Robinson KS, Lewandowski B. Application of diagnostic clinical model for the management of hospitalized medical patients with suspected deep vein thrombosis. Thromb Haemost 1999; 81: 4937.
  • 10
    Wells PS, Anderson DR, Bormanis J, Guy F, Mitchell M, Gray L, Clement C, Robinson KS, Lewandowski B. Value of assessment of pretest probability of deep vein thrombosis in clinical management. Lancet 1997; 350: 17958.
  • 11
    Goldhaber SZ, Dunn K, MacDougall RC. New onset of venous thromboembolism among hospitalized patients at Brigham and Women’s Hospital is caused more often by prophylaxis failure than by withholding treatment. Chest 2000; 118: 16804.
  • 12
    Kahn SR, Panju A, Geerts A, Pineo GF, Desjardins L, Turpie AGG, Glezer S, Thabane L, Sebaldt RJ, CURVE study investigators. Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada. Thromb Res 2007; 119: 14555.
  • 13
    Stratton MA, Anderson FA, Bussey HI, Caprini J, Comerota A, Haines ST, Hawkins DW, O’Connell MB, Smith RC, Stringer KA. Prevention of venous thromboembolism: adherence to the 1995 American College of Chest Physicians consensus guidelines for surgical patients. Arch Intern Med 2000; 160: 33440.
  • 14
    Caprini JA, Arcelus J, Sehgal LR, Cohen EB, Reyna JJ. The use of low molecular weight heparins for the prevention of postoperative venous thromboembolism in general surgery. A survey of practice in the United States. Int Angiol 2002; 21: 7885.
  • 15
    Mesko JW, Brand RA, Iorio R, Gradisar I, Heekin R, Leighton R, Thornberry R. Venous thromboembolic disease management patterns in total hip arthroplasty and total knee arthroplasty patients: a survey of the AAHKS membership. J Arthroplasty 2001; 16: 67988.
  • 16
    Wein L, Wein S, Haas SJ, Shaw J, Krum H. Pharmacological venous thromboembolism prophylaxis in hospitalized medical patients: a meta-analysis of randomized controlled trials. Arch Intern Med 2007; 167: 147686.
  • 17
    Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomized controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 1999; 354: 1896900.
  • 18
    Kearon C, Julian JA, Newman TE, Ginsberg JS. Noninvasive diagnosis of deep venous thrombosis. McMaster Diagnostic Imaging Practice Guidelines Initiative. Ann Intern Med 1998; 128: 66377.
  • 19
    Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 112.
  • 20
    Intention to treat issues. Cochrane Handbook for Systematic Reviews of Interventions 4.26; section 8.4. In: HigginsJ, GreenS, editors. The Cochrane Library Issue 1, 2007.
  • 21
    Leizorovicz A, Cohen AT, Turpie AG, Olsson C, Vaitkus PT, Goldhaber SZ, PREVENT Medical Thromboprophylaxis Study Group. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004; 110: 8749.
  • 22
    Samama MM, Cohen AT, Darmon J, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Nguyen H, Olsson CG, Turpie AG, Weisslinger N. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Eng J Med 1999; 341: 793800.
  • 23
    Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, Turpie AG, Egberts JF, Lensing AW, ARTEMIS Investigators. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomized placebo controlled trial. BMJ 2006; 332: 3259.
  • 24
    Fraisse F, Holzapfel L, Coulaud J, Simonneau G, Bedock B, Feissel M, Herbecq P, Pordes R, Poussel JF, Roux L. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. Am J Respir Crit Care Med 2000; 161: 110914.
  • 25
    Vaitkus PT, Leizorovicz A, Goldhaber SZ. Rationale and design of a clinical trial of a low-molecular-weight heparin in preventing clinically important venous thromboembolism in medical patients: the prospective evaluation of dalteparin efficacy for prevention of venous thromboembolism in immobilized patients trial (the PREVENT study). Vasc Med 2002; 7: 26973.
  • 26
    Sandset PM, Dahl T, Stiris M, Rostad B, Scheel B, Abildgaard U. A double-blind and randomized placebo-controlled trial of low-molecular weight heparin once daily to prevent deep vein thrombosis in acute ischemic stroke. Semin Thromb Hemost 1990; 16: 2533.
  • 27
    Lederle FA, Sacks JM, Landefeld CS, Steinberg N, Peters RW, Eid AA, Sebastian J, Stasek JE Jr, Fye CL. The prophylaxis of medical patients for thromboembolism pilot study. Am J Med 2006; 119: 549.
  • 28
    Mahe I, Bergmann JF, D’Azemar P, Vaissie JJ, Caulin C. Lack of effect of a low-molecular-weight heparin (nadroparin) on mortality in bedridden medical in-patients: a prospective randomized double-blind study. Eur J Clin Pharmacol 2005; 61: 34751.
  • 29
    Kakkar AK, Levine MN, Kadziola Z, Lemoine NR, Low V, Patel HK, Rustin G, Thomas M, Quigley M, Williamson RC. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004; 22: 19448.
  • 30
    Pambianco G, Orchard T, Landau P. Deep vein thrombosis: prevention in stroke patients during rehabilitation. Arch Phys Med Rehabil 1995; 76: 32430.
  • 31
    Turpie AG, Levine MN, Hirsh J, Carter CJ, Jay RM, Powers PJ, Andrew M, Magnani HN, Hull RD, Gent M. Double-blind randomized trial of Org 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke. Lancet 1987; 1: 5236.
  • 32
    Turpie AGG. Orgaran in the prevention of deep vein thrombosis in stroke patients. Haemostasis 1992; 22: 928.
  • 33
    Poniewierski M, Barthels M, Kuhn M, Poliwoda H. Effectiveness of low molecular weight heparin (Fragmin) in the prevention of thromboembolism in internal medicine patients. A randomized double-blind study [German]. Med Klin 1988; 83: 2415.
  • 34
    Dahan R, Houlbert D, Caulin C, Cuzin E, Viltart C, Woler M, Segrestaa JM. Prevention of deep vein thrombosis in elderly medical in-patients by a low molecular weight heparin: a randomized double-blind trial. Haemostasis 1986; 16: 15964.
  • 35
    McCarthy ST, Turner J. Low-dose subcutaneous heparin in the prevention of deep vein thrombosis and pulmonary emboli following acute stroke. Age Ageing 1986; 15: 848.
  • 36
    Belch JJ, Lowe GD, Ward AG, Forbes CD, Prentice CR. Prevention of deep vein thrombosis in medical patients by low-dose heparin. Scott Med J 1981; 26: 1157.
  • 37
    McCarthy ST, Turner JJ, Robertson D, Hawkey CJ, Macey DJ. Low-dose heparin as a prophylaxis against deep vein thrombosis after acute stroke. Lancet 1977; 2: 8001.
  • 38
    Warlow C, Terry G, Kenmure AC, Beattie AG, Ogston D, Douglas AS. A double-blind trial of low doses of subcutaneous heparin in the prevention of deep vein thrombosis after myocardial infarction. Lancet 1973; 2: 9346.
  • 39
    Handley AJ, Emerson PA, Fleming PR. Heparin in the prevention of deep vein thrombosis after myocardial infarction. BMJ 1972; 2: 4368.
  • 40
    Kakkar VV. Efficacy of low-dose heparin prophylaxis. Current Ther Res 1975; 18 (1 Pt 1): 620.
  • 41
    Hull RD, Schellong SM, Tapson VF, Monreal M, Samama MM, Turpie AG, Wildgoose P, Yusen RD. Extended-duration thromboprophylaxis in acutely ill medical patients with recent reduced mobility: methodology for the EXCLAIM study. J Thromb Thrombolysis 2006; 22: 318.
  • 42
    Elias A, Milandre L, Lagrange G, Aillaud MF, Alonzo B, Toulemonde F, Juhan-Vague I, Khalil R, Bayrou B, Serradimigni A. Prevention of deep venous thrombosis of the leg by a very low molecular weight heparin fraction (CY 222) in patients with hemiplegia following cerebral infarction: a randomized pilot study (30 patients) [French]. Rev Med Interne 1990; 11: 958.
  • 43
    Hull RD, Schellong SM, Tapson VF, Monreal M, Samama MM, Turpie AGG, Yusen RD. Late Breaking Clinical Trial: Extended-Duration Venous Thromboembolism (VTE) Prophylaxis in Acutely Ill Medical Patients with Recent Reduced Mobility: The EXCLAIM Study. Proceedings of the 7th International Society on Thrombosis and Haemostasis Conference, Geneva: Blackwell Publishing, July 6–12, 2007.
  • 44
    Kamphuisen PW, Agnelli G. What is the optimal pharmacological prophylaxis for the prevention of deep vein thrombosis and pulmonary embolism in patients with acute ischemic stroke? Thromb Res 2007; 119: 26574.
  • 45
    Quinlan DJ, Eikelboom JW, Dahl OE, Eriksson BI, Sidhu PS, Hirsh J. Association between asymptomatic deep vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgery. J Thromb Haemost 2007; 5: 143843.
  • 46
    Spencer FA, Lessard D, Emery C, Reed G, Goldberg RJ. Venous thromboembolism in the outpatient setting. Arch Intern Med 2007; 167: 14715.
  • 47
    Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3: 6924.